EP 0573581 A4 19940629 - COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN
Title (en)
COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN
Publication
Application
Priority
- US 66155491 A 19910226
- US 74763591 A 19910820
Abstract (en)
[origin: WO9214453A1] Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.
IPC 1-7
IPC 8 full level
A61K 31/135 (2006.01); A61K 31/155 (2006.01); A61K 31/165 (2006.01); A61K 31/18 (2006.01); A61K 31/335 (2006.01); A61K 31/395 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/425 (2006.01); A61K 31/44 (2006.01); A61K 31/4402 (2006.01); A61K 31/4412 (2006.01); A61K 31/4418 (2006.01); A61K 31/445 (2006.01); A61K 31/47 (2006.01); A61K 31/475 (2006.01); A61K 31/48 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/54 (2006.01); A61K 31/55 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01); C07D 207/08 (2006.01); C07D 207/16 (2006.01); C07D 213/54 (2006.01); C07D 213/79 (2006.01); C07D 213/83 (2006.01); C07D 239/78 (2006.01)
CPC (source: EP US)
A61K 31/135 (2013.01 - EP); A61K 31/155 (2013.01 - EP); A61K 31/165 (2013.01 - EP); A61K 31/18 (2013.01 - EP); A61K 31/335 (2013.01 - EP); A61K 31/395 (2013.01 - EP US); A61K 31/40 (2013.01 - EP); A61K 31/415 (2013.01 - EP); A61K 31/425 (2013.01 - EP); A61K 31/44 (2013.01 - EP); A61K 31/445 (2013.01 - EP); A61K 31/47 (2013.01 - EP); A61K 31/475 (2013.01 - EP); A61K 31/48 (2013.01 - EP); A61K 31/495 (2013.01 - EP); A61K 31/505 (2013.01 - EP); A61K 31/54 (2013.01 - EP); A61K 31/55 (2013.01 - EP); A61P 25/02 (2017.12 - EP); A61P 25/04 (2017.12 - EP)
Citation (search report)
- [X] A.L. CURTIS ET AL.: "Evidence for alpha adrenoceptor modulation of the nociceptive jaw-opening reflex in rats and rabbits.", J. PHARMACOL. EXP. THER., vol. 238, no. 2, 1986, pages 576 - 579
- [X] J. SAGEN ET AL.: "Evidence for pain modulation by pre-and postsynaptic noradrenergic receptors in the medulla oblongata.", BRAIN RES., vol. 331, no. 2, 1985, pages 285 - 293
- [X] M. ISHIZUKI: "Clinical application of guanethidine ointment to the treatment of painful states and allodynia.", CLIN. J. PAIN, vol. 4, no. 4, 1988, pages 261
- See references of WO 9214453A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
DOCDB simple family (publication)
WO 9214453 A1 19920903; CA 2104873 A1 19920903; CA 2104873 C 20000523; EP 0573581 A1 19931215; EP 0573581 A4 19940629; JP H06507392 A 19940825
DOCDB simple family (application)
US 9201543 W 19920226; CA 2104873 A 19920226; EP 92907852 A 19920226; JP 50739292 A 19920226